(Yicai) March 23 -- Shares in Grand Pharma tumbled today despite the Chinese drugmaker being given the greenlight to take its first-in-class eye treatment for demodex blepharitis, a chronic eyelid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results